NCTN Gynecologic Cancer Trials Portfolio (Open as of 8/26/2019)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

**Ovarian cancer**
- **Epithelial**
  - Newly diagnosed
    - Any histology
      - NRG-GY007
    - Low grade serous
      - NRG-GY019*
  - Recurrent
    - Platinum resistant
      - NRG-GY009
    - All histology
      - EAE161
      - HGSOC
      - NRG-GY005 (COCOS)
- **Non-Epithelial**
  - Stromal, Newly diagnosed
    - GOG-0264
  - Low-standard risk
    - AGCT1531
  - Intermediate and poor risk metastatic
    - AGCT1532
- **Germ cell**

**Cervical cancer (sq, adeno, adeno sq)**
- Organ confined, High risk
  - GOG-0263
  - RTOG-0724
- Newly diagnosed, Locally advanced
  - NRG-GY017
  - NRG-GY006

**Vaginal cancer**
- Newly diagnosed, Locally advanced

**Uterine cancer**
- First recurrence, Local only
  - GOG-0238
- Stage III/IV or recurrent
  - NRG-GY018
- Recurrent
  - Any histology
    - NRG-GY012
  - Endometrioid
    - NRG-GY014

**Vulvar cancer**
- Locally advanced
  - GOG-0279
- Recurrent
  - S1609 (DART)

**Trophoblastic tumors**
- Recurrent
  - S1609 (DART)

*: No Clinicaltrials.gov link yet.
NCTN Gynecologic Cancer Trials Portfolio (Open as of 8/26/2019)
Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH)  S1609 (DART)
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGCT1531</td>
<td>III</td>
<td>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors</td>
</tr>
<tr>
<td>AGCT1532</td>
<td>III</td>
<td>A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors</td>
</tr>
<tr>
<td>EAE161</td>
<td>II</td>
<td>Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma</td>
</tr>
<tr>
<td>GOG-0238</td>
<td>II</td>
<td>A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus</td>
</tr>
<tr>
<td>GOG-0263</td>
<td>III</td>
<td>Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01110451)</td>
</tr>
<tr>
<td>GOG-0264</td>
<td>II</td>
<td>A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo naive Sex Cord-Stromal Tumors of the Ovary</td>
</tr>
<tr>
<td>GOG-0279</td>
<td>II</td>
<td>A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva</td>
</tr>
<tr>
<td>NRG-GY005</td>
<td>II/III</td>
<td>A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)</td>
</tr>
<tr>
<td>NRG-GY006</td>
<td>II</td>
<td>A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer</td>
</tr>
<tr>
<td>NRG-GY007</td>
<td>I/II</td>
<td>A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</td>
</tr>
<tr>
<td>NRG-GY009</td>
<td>II/III</td>
<td>A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer</td>
</tr>
<tr>
<td>NRG-GY012</td>
<td>II</td>
<td>A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer</td>
</tr>
<tr>
<td>NRG-GY014</td>
<td>II</td>
<td>A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma</td>
</tr>
<tr>
<td>NRG-GY016</td>
<td>II</td>
<td>A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary</td>
</tr>
<tr>
<td>NRG-GY017</td>
<td>I</td>
<td>Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer</td>
</tr>
<tr>
<td>NRG-GY018</td>
<td>III</td>
<td>A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer</td>
</tr>
<tr>
<td>NRG-GY019</td>
<td>III</td>
<td>A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum</td>
</tr>
<tr>
<td>RTOG-0724</td>
<td>III</td>
<td>Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy</td>
</tr>
<tr>
<td>S1609</td>
<td>II</td>
<td>DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors</td>
</tr>
<tr>
<td>EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
</tbody>
</table>